Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Executive Summary
Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)